Features of Circadian Rhythms in Patients with Cerebrovascular Diseases

The chapter describes in detail the pathogenetic role of desynchronosis in the development of cerebrovascular diseases (CVD). The data of domestic and foreign literature on the study of desynchronosis are presented. The role of melatonin in the regulation of circadian rhythms (CR) is shown. Pathological changes in CR affect sleep disturbance, emotional and cognitive disorders. It is demonstrated the need of the further study of the prevalence and structure of desynchronosis in patients with CVD. The search of the most significant factors of desynchronosis development in patients with vascular diseases is of great scientific and practical significance. The importance of creating and introducing diagnostic and therapeutic algorithms for chronodiagnostics and chronotherapy of CVD into everyday practical activities. The effectiveness of melatonin for the normalization of sleep and CR in patients with insomnia, acute stroke, depressive disorders is shown. Complex therapy of the patients with CVD taking into account chronobiological disorders allows to eliminate the adverse effect of sleep disorders and CR on the regulation of the cardiovascular system and improve the efficiency of rehabilitation

Study of the group properties of the Sircar-Papanicolaou model in case of a nonlinear utility function

In this paper it is considered the Sircar-Papanicolaou model wich takesinto account a feedback effect of dynamic hedging strategies of pro-gramme traders. Using the Lie group analysis we describe the symmetrygroup of the main equation of the concerned model. We reduce this par-tial differential equation to the ordinary differential equations by usingcorresponding invariants of the subgroups of the main symmetry group

Growing Maize Root: Lectins Involved in Consecutive Stages of Cell Development

Proteins that carry specific carbohydrate-binding lectin domains have a great variety and are ubiquitous across the plant kingdom. In turn, the plant cell wall has a complex carbohydrate composition, which is subjected to constant changes in the course of plant development. In this regard, proteins with lectin domains are of great interest in the context of studying their contribution to the tuning and monitoring of the cell wall during its modifications in the course of plant organ development. We performed a genome-wide screening of lectin motifs in the Zea mays genome and analyzed the transcriptomic data from five zones of primary maize root with cells at different development stages. This allowed us to obtain 306 gene sequences encoding putative lectins and to relate their expressions to the stages of root cell development and peculiarities of cell wall metabolism. Among the lectins whose expression was high and differentially regulated in growing maize root were the members of the EUL, dirigent–jacalin, malectin, malectin-like, GNA and Nictaba families, many of which are predicted as cell wall proteins or lectin receptor-like kinases that have direct access to the cell wall. Thus, a set of molecular players was identified with high potential to play important roles in the early stages of root morphogenesis

Evidence and quantitative evaluation of tensile maturation strain in flax phloem through longitudinal splitting

International audienceThe stems of flax (Linum usitatissimum L. cv. 'Mogilevsky') contain many gelatinous fibers in their phloem. These fibers are important for the mechanical stability of the plant as well as for industrial applications. Gelatinous fibers are known to have a motor function in the xylem of trees and in many plant organs. This function arises from the so-called maturation strain, i.e., the tendency of the gelatinous layer to shrink during fiber maturation, resulting in a state of residual tensile stress. However, the occurrence of tensile maturation strain in flax phloem fibers remains to be demonstrated, and its magnitude has never been evaluated. Here we present a novel method to highlight and quantify this strain. The method consists in splitting a stem segment longitudinally, and measuring the curvature of the half segments through their opening distance. By using a mechanical model, the maturation strain can be calculated from the curvature, the dimensions of the component tissues, and their elastic properties. The model is validated by the agreement between model predictions and observations. The splitting experiment provides qualitative evidence that flax phloem develops tensile stress during maturation, just as xylem gelatinous fibers do. Calculations enable quantitative estimation of the maturation strain. The magnitude of this strain for the material studied is, on average, -1.5%

Effect of Grain Size on the Properties of Aluminum Matrix Composites with Graphene

The structure and mechanical properties of composites consisting of a metal matrix based on aluminum and its alloys of different compositions (AA-3003 and AA-5154) and graphene synthes sized in situ under a layer of molten salts were investigated depending on the chemical composition and grain size of the matrix. Aluminum matrix composites of three compositions were studied in as-cast coarse-grained, deformed fine-grained (grain size ε˙ from 1.8 − 4.7 × 103 to 1.6 − 2.4 × 105 s−1. It was found that grain refinement induced a sharp increase in the hardness of composites with various compositions (by a factor of 1.6–2.6). A correlation of the elastic-plastic properties of the aluminum matrix composites with the grain sizes and chemical compositions of the matrices was established. A transition from coarse-grained to sub microcrystalline structure was shown to improve the elastic-plastic properties on average by a factor of 1.5. It was proved that the reinforcing effect of graphene increased with the decreasing grain size of the matrix. Mechanisms of reinforcement of the aluminum matrix composites using graphene were proposed

The Clouds of Venus – an overview of Venus Express results

International audienceVenus is completely enveloped by clouds. The main cloud layers stretch from altitudes of 48 – 75 km, with additional tenuous hazes found at altitudes 30 – 100 km. Clouds play a crucial role in governing atmospheric circulation, chemistry and climate on all planets, but particularly so on Venus due to the optical thickness of the atmosphere. The European Space Agency’s Venus Express (VEx) satellite has carried out a wealth of observations of Venus clouds since its arrival at Venus in April 2006. Many VEx observations are relevant to cloud science – from imagers and spectrometers to solar, stellar and radio occultation – each covering different altitude ranges, spectral ranges and atmospheric constituents.We have formed an International Team at the International Space Science Institute to bring together scientists from each of the relevant Venus Express investigation teams as well as from previous missions, as well as those developing computational and analytical models of clouds and hazes. The aims of the project are (1) to perform intercomparisons of cloud parameters measured using different techniques, (1) to create self-consistent reference cloud/haze models which capture not only a mean cloud structure but also its main modes of variability; and (2) to bring together modelers and observers, to reach an understanding of clouds and hazes on Venus which matches all observables and is physically consistent.This talk will present an overview of Venus Express cloud observations of all different types, and discuss progress towards a new reference cloud model to be submitted to an update of the Venus International Reference Atmosphere

Adaptive pathways: possible next steps for payers in preparation for their potential implementation

Medicines receiving a conditional marketing authorization through Medicines Adaptive Pathways to Patients (MAPPs) will be a challenge for payers. The “introduction” of MAPPs is already seen by the European Medicines Agency (EMA) as a fait accompli, with payers not consulted or involved. However, once medicines are approved through MAPPs, they will be evaluated for funding by payers through different activities. These include Health Technology Assessment (HTA) with often immature clinical data and high uncertainty, financial considerations, and negotiations through different types of agreements, which can require monitoring post launch. Payers have experience with new medicines approved through conditional approval, and the fact that MAPPs present additional challenges is a concern from their perspective. There may be some activities where payers can collaborate. The final decisions on whether to reimburse a new medicine via MAPPs will have more variation than for medicines licensed via conventional processes. This is due not only to increasing uncertainty associated with medicines authorized through MAPPs but also differences in legal frameworks between member states. Moreover, if the financial and side-effect burden from the period of conditional approval until granting full marketing authorization is shifted to the post-authorization phase, payers may have to bear such burdens. Collection of robust data during routine clinical use is challenging along with high prices for new medicines during data collection. This paper presents the concept of MAPPs and possible challenges. Concerns and potential ways forward are discussed and a number of recommendations are presented from the perspective of payers

Adaptive Pathways : Possible Next Steps for Payers in Preparation for Their Potential Implementation

Altres ajuts: There was no funding body. However, the writeup work was in part supported by grants from the Karolinska Institutet, Sweden.Medicines receiving a conditional marketing authorization through Medicines Adaptive Pathways to Patients (MAPPs) will be a challenge for payers. The "introduction" of MAPPs is already seen by the European Medicines Agency (EMA) as a fait accompli, with payers not consulted or involved. However, once medicines are approved through MAPPs, they will be evaluated for funding by payers through different activities. These include Health Technology Assessment (HTA) with often immature clinical data and high uncertainty, financial considerations, and negotiations through different types of agreements, which can require monitoring post launch. Payers have experience with new medicines approved through conditional approval, and the fact that MAPPs present additional challenges is a concern from their perspective. There may be some activities where payers can collaborate. The final decisions on whether to reimburse a new medicine via MAPPs will have more variation than for medicines licensed via conventional processes. This is due not only to increasing uncertainty associated with medicines authorized through MAPPs but also differences in legal frameworks between member states. Moreover, if the financial and side-effect burden from the period of conditional approval until granting full marketing authorization is shifted to the post-authorization phase, payers may have to bear such burdens. Collection of robust data during routine clinical use is challenging along with high prices for new medicines during data collection. This paper presents the concept of MAPPs and possible challenges. Concerns and potential ways forward are discussed and a number of recommendations are presented from the perspective of payers

Long-term efficacy and safety of eslicarbazepine acetate monotherapy for adults with newly diagnosed focal epilepsy: An open-label extension study

Objective: To assess the efficacy, safety, and tolerability of eslicarbazepine acetate (ESL) monotherapy during long-term treatment. Methods: An open-label extension (OLE) study was conducted in adults completing a phase 3, randomized, double-blind, noninferiority trial, during which they had received monotherapy with either once-daily ESL or twice-daily controlled-release carbamazepine (CBZ-CR) for newly diagnosed focal epilepsy. In the OLE study, all patients received ESL (800-1600 mg/d) for 2 years. Primary efficacy outcome was retention time (from baseline of the OLE study). Secondary efficacy assessments included seizure freedom rate (no seizures during the OLE study) and responder rate (≥50% seizure frequency reduction from baseline of double-blind trial). Safety assessments included evaluation of treatment-emergent adverse events (TEAEs). Results: Of 206 randomized patients, 96 who received ESL in the double-blind trial (ESL/ESL) and 88 who received CBZ-CR in the double-blind trial (CBZ-CR/ESL) were treated with ESL monotherapy (89.3% overall). Treatment retention time was similar between groups, with low probability of ESL withdrawal overall (80% in both groups throughout the study. Incidence of serious TEAEs was similar between groups (7.3% vs 5.7%; 0% vs 1.1% possibly related), as were the incidences of TEAEs considered at least possibly related to treatment (17.7% vs 18.2%) and TEAEs leading to discontinuation (3.1% vs 4.5%). The types of TEAEs were generally consistent with the known safety profile of ESL. Significance: ESL monotherapy was efficacious and generally well tolerated over the long term, including in patients who transitioned from CBZ-CR monotherapy. No new safety concerns emerged